DOI: 10.1186/s13073-026-01630-0 The study received funding from Wellcome, Medical Research Council, European Union Horizon 2020 Programme, the National Institutes of Health (grants U01-DK105535, U01-DK085545 and UM-1DK126185), the National Institute for Health Research Oxford Biomedical Research Centre, the Canadian Institutes of Health Research, the Novo Nordisk Foundation, Boehringer Ingelheim and Diabetes Australia
10.1016/S2213-8587(19)30184-6 8 ArodaV
Pharmacovigilance studies indicate that GLP-1RAs, with the exception of albiglutide, demonstrate potential associations with pancreatic cancer risk, particularly evident in exenatide-treated patients who exhibit elevated cancer incidence rates
There is no medical rule that says you must choose one or the other
503A pharmacies compound individual prescriptions and are regulated by state boards
If metabolic optimization and mitochondrial support are priorities, tirzepatide niacinamide or NAD+ precursor formulations are logical choices